Financhill
Sell
48

IMRX Quote, Financials, Valuation and Earnings

Last price:
$2.00
Seasonality move :
-14.17%
Day range:
$1.79 - $2.08
52-week range:
$1.00 - $7.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
186.84x
P/B ratio:
1.08x
Volume:
678.7K
Avg. volume:
708K
1-year change:
-70.07%
Market cap:
$62.3M
Revenue:
--
EPS (TTM):
-$1.97

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IMRX
Immuneering
-- -$0.55 -- -24.68% --
ANTX
AN2 Therapeutics
-- -$0.39 -- -42.31% --
FOLD
Amicus Therapeutics
$135M $0.05 28.06% -81.83% --
NBY
NovaBay Pharmaceuticals
$2.6M -$0.31 -60.77% -99.16% --
PTCT
PTC Therapeutics
$171.8M -$1.66 -37.97% -75.73% --
PTN
Palatin Technologies
-- -$0.51 -100% -25% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IMRX
Immuneering
$2.01 -- $62.3M -- $0.00 0% 186.84x
ANTX
AN2 Therapeutics
$1.26 -- $37.6M -- $0.00 0% --
FOLD
Amicus Therapeutics
$9.80 -- $2.9B -- $0.00 0% 6.02x
NBY
NovaBay Pharmaceuticals
$0.53 -- $2.6M -- $0.00 0% 0.06x
PTCT
PTC Therapeutics
$46.24 -- $3.6B -- $0.00 0% 3.92x
PTN
Palatin Technologies
$0.97 -- $18.9M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IMRX
Immuneering
-- 4.930 -- --
ANTX
AN2 Therapeutics
-- 1.207 -- --
FOLD
Amicus Therapeutics
68.53% 1.122 12.21% 2.20x
NBY
NovaBay Pharmaceuticals
4.54% 0.704 1.51% 0.75x
PTCT
PTC Therapeutics
-37.06% 0.081 9.99% 1.99x
PTN
Palatin Technologies
-- -0.872 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IMRX
Immuneering
-- -$15.3M -- -- -- -$13.5M
ANTX
AN2 Therapeutics
-- -$11.8M -- -- -- -$12M
FOLD
Amicus Therapeutics
$128.2M $24.8M -19.5% -71.17% 13.76% -$23.3M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTCT
PTC Therapeutics
$185.9M -$52M -425.51% -- -28.65% -$87.8M
PTN
Palatin Technologies
$350K -$7.8M -- -- -2356.3% -$7M

Immuneering vs. Competitors

  • Which has Higher Returns IMRX or ANTX?

    AN2 Therapeutics has a net margin of -- compared to Immuneering's net margin of --. Immuneering's return on equity of -- beat AN2 Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IMRX
    Immuneering
    -- -$0.49 --
    ANTX
    AN2 Therapeutics
    -- -$0.43 --
  • What do Analysts Say About IMRX or ANTX?

    Immuneering has a consensus price target of --, signalling upside risk potential of 519.29%. On the other hand AN2 Therapeutics has an analysts' consensus of -- which suggests that it could grow by 111.64%. Given that Immuneering has higher upside potential than AN2 Therapeutics, analysts believe Immuneering is more attractive than AN2 Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMRX
    Immuneering
    3 2 0
    ANTX
    AN2 Therapeutics
    0 0 0
  • Is IMRX or ANTX More Risky?

    Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AN2 Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IMRX or ANTX?

    Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AN2 Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. AN2 Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMRX or ANTX?

    Immuneering quarterly revenues are --, which are smaller than AN2 Therapeutics quarterly revenues of --. Immuneering's net income of -$14.6M is lower than AN2 Therapeutics's net income of -$12.7M. Notably, Immuneering's price-to-earnings ratio is -- while AN2 Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 186.84x versus -- for AN2 Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMRX
    Immuneering
    186.84x -- -- -$14.6M
    ANTX
    AN2 Therapeutics
    -- -- -- -$12.7M
  • Which has Higher Returns IMRX or FOLD?

    Amicus Therapeutics has a net margin of -- compared to Immuneering's net margin of -4.76%. Immuneering's return on equity of -- beat Amicus Therapeutics's return on equity of -71.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMRX
    Immuneering
    -- -$0.49 --
    FOLD
    Amicus Therapeutics
    90.62% -$0.02 $568.3M
  • What do Analysts Say About IMRX or FOLD?

    Immuneering has a consensus price target of --, signalling upside risk potential of 519.29%. On the other hand Amicus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 76.87%. Given that Immuneering has higher upside potential than Amicus Therapeutics, analysts believe Immuneering is more attractive than Amicus Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMRX
    Immuneering
    3 2 0
    FOLD
    Amicus Therapeutics
    0 0 0
  • Is IMRX or FOLD More Risky?

    Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.114%.

  • Which is a Better Dividend Stock IMRX or FOLD?

    Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMRX or FOLD?

    Immuneering quarterly revenues are --, which are smaller than Amicus Therapeutics quarterly revenues of $141.5M. Immuneering's net income of -$14.6M is lower than Amicus Therapeutics's net income of -$6.7M. Notably, Immuneering's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 186.84x versus 6.02x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMRX
    Immuneering
    186.84x -- -- -$14.6M
    FOLD
    Amicus Therapeutics
    6.02x -- $141.5M -$6.7M
  • Which has Higher Returns IMRX or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Immuneering's net margin of -49.65%. Immuneering's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IMRX
    Immuneering
    -- -$0.49 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About IMRX or NBY?

    Immuneering has a consensus price target of --, signalling upside risk potential of 519.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Immuneering, analysts believe NovaBay Pharmaceuticals is more attractive than Immuneering.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMRX
    Immuneering
    3 2 0
    NBY
    NovaBay Pharmaceuticals
    0 0 0
  • Is IMRX or NBY More Risky?

    Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

  • Which is a Better Dividend Stock IMRX or NBY?

    Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMRX or NBY?

    Immuneering quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Immuneering's net income of -$14.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Immuneering's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 186.84x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMRX
    Immuneering
    186.84x -- -- -$14.6M
    NBY
    NovaBay Pharmaceuticals
    0.06x -- $2.4M -$1.2M
  • Which has Higher Returns IMRX or PTCT?

    PTC Therapeutics has a net margin of -- compared to Immuneering's net margin of -54.2%. Immuneering's return on equity of -- beat PTC Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IMRX
    Immuneering
    -- -$0.49 --
    PTCT
    PTC Therapeutics
    94.49% -$1.39 -$769.2M
  • What do Analysts Say About IMRX or PTCT?

    Immuneering has a consensus price target of --, signalling upside risk potential of 519.29%. On the other hand PTC Therapeutics has an analysts' consensus of -- which suggests that it could grow by 26.98%. Given that Immuneering has higher upside potential than PTC Therapeutics, analysts believe Immuneering is more attractive than PTC Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMRX
    Immuneering
    3 2 0
    PTCT
    PTC Therapeutics
    6 3 1
  • Is IMRX or PTCT More Risky?

    Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.101%.

  • Which is a Better Dividend Stock IMRX or PTCT?

    Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMRX or PTCT?

    Immuneering quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Immuneering's net income of -$14.6M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Immuneering's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 186.84x versus 3.92x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMRX
    Immuneering
    186.84x -- -- -$14.6M
    PTCT
    PTC Therapeutics
    3.92x -- $196.8M -$106.7M
  • Which has Higher Returns IMRX or PTN?

    Palatin Technologies has a net margin of -- compared to Immuneering's net margin of -2357.27%. Immuneering's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IMRX
    Immuneering
    -- -$0.49 --
    PTN
    Palatin Technologies
    -- -$0.39 -$111.5K
  • What do Analysts Say About IMRX or PTN?

    Immuneering has a consensus price target of --, signalling upside risk potential of 519.29%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Immuneering, analysts believe Palatin Technologies is more attractive than Immuneering.

    Company Buy Ratings Hold Ratings Sell Ratings
    IMRX
    Immuneering
    3 2 0
    PTN
    Palatin Technologies
    0 0 0
  • Is IMRX or PTN More Risky?

    Immuneering has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

  • Which is a Better Dividend Stock IMRX or PTN?

    Immuneering has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immuneering pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IMRX or PTN?

    Immuneering quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Immuneering's net income of -$14.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Immuneering's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immuneering is 186.84x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IMRX
    Immuneering
    186.84x -- -- -$14.6M
    PTN
    Palatin Technologies
    -- -- $350K -$7.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.55% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock